Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin - Bertin Instruments

    Scientific publications

    Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

    Shripad V. Bhagwat1, Prafulla C. Gokhale3, Andrew P. Crew2, Andy Cooke3, Yan Yao1, Christine Mantis3, Jennifer Kahler1, Jennifer Workman3, Mark Bittner3, Lorina Dudkin4, David M. Epstein1, Neil W. Gibson1, Robert Wild3, Lee D. Arnold2, Peter J. Houghton4, and Jonathan A. Pachter1
    Sources: 1Cancer Biology and 2Cancer Chemistry, OSI Pharmaceuticals Inc., Farmingdale, New York; 3In vivo Pharmacology,, OSI Pharmaceuticals Inc., Boulder, Colorado; and 4Center for Childhood Cancer, Nationwide Children's Hospital, Columbus, Ohio
    Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). Received December 9, 2010. Revision received June 2, 2011. Accepted June 8, 2011. 2011; doi: 10.1158/15Life Sciences-7163.MCT-10-1099 Mol Cancer Ther August 2011 10; 1394

    Sample name

    Human tissues

    ANY QUESTIONS? CONTACT AN EXPERT

    Please fill in this form if you wish to contact our sales team or receive further information.

    My Account
    Forgot password ?

    Add a question !

    Add a question